stockrowKiniksa Pharmaceuticals International, plc (KNSA) vs Indivior Pharmaceuticals Inc. (SUPN)
- Kiniksa Pharmaceuticals International, plc KNSA 88.50 −7.93%
- Indivior Pharmaceuticals Inc. SUPN 28.21 +0.21%
Kiniksa Pharmaceuticals International, plc and Indivior Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc is the larger, with a market value of $6.9B against $5.6B — 1.3× the size. Indivior Pharmaceuticals Inc. trades at the lower P/E: 7.6× against 62.1×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.2% against 16.4%. Indivior Pharmaceuticals Inc. has the higher net margin (32.9% vs 11.6%) and the higher return on invested capital (283.0% vs 57.7%). Across the 19 metrics below, Indivior Pharmaceuticals Inc. leads on 11 and Kiniksa Pharmaceuticals International, plc on 8.
Valuation
Profitability
| Metric | KNSA | SUPN | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 90.16% | 84.85% | 53.51% |
| Operating margin | 13.79% | 40.57% | 0.00% |
| Net margin | 11.58% | 32.85% | (2.45%) |
| Free cash flow margin | 20.85% | 2.26% | 0.00% |
| Return on equity | 17.59% | (337.83%) | (0.80%) |
| Return on assets | 12.92% | 32.82% | (1.67%) |
| Return on invested capital | 57.65% | 283.03% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack